No abstract available.
Animals ; Dizocilpine Maleate* ; Rats* ; Spinal Cord*

PURPOSE: Sclerotherapy for renal cysts was performed, using 50% acetic acid as new sclerosing agent. Wereport the methods and results of this procedure. MATERIALS AND METHODS: Fifteen patients underwent sclerotherapyfor renal cyst, using 50% acetic acid. Because four patients were lost to follow-up, only 11 of the 15 wereincluded in this study. The renal cysts, including one infected case, were diagnosed by ultrasonograpy (n=10) ormagnetic resonance imaging (n=1). The patient group consisted of four men and seven women (mean age, 59 years;range, 23-77). At first, the cyst was completely aspirated, and 25 volume% of aspirated volume was replaced with50% sterile acetic acid through the drainage catheter. During the following 20 minutes, the patient changedposition, and the acetic acid was then removed from the cyst. Finally, the drainage catheter was removed, aftercleaning the cyst with saline. After treatment of infection by antibiotics and catheter drainage for 7 days,sclerotherapy in the infected case followed the same procedure. In order to observe changes in the size of renalcysts and recurrence, all patients were followed up by ultrasound between 2 and 8 months. We defined response totherapy as follows: complete regression as under 5 volume%, partial regression as 5-50 volume% and no response asmore than 50 volume% of initial cyst volume. RESULTS: No clinically significant complication occured during theprocedures or follow-up periods. All cysts regressed completely during follow-up of 8 months. Complete regressionoccurred as follows : two cysts at 2 months, seven cysts at 4 months, two cysts at 6 months. Two cysts showedresidues at the last follow-up, at 4 and 6 months, respectiivery. The volume of residual cysts decreased to under5 volume% of initial volume, however. Completely regressed cysts did not recurr during follow-up. CONCLUSION: Acetic acid sclerotherapy for renal cysts showed good results, regardless of the dilntion of sclersoing agent withresidual cyst fluid, and no significant complications. the procedure, therefore, appears to provide effectivetherapy for renal cysts.
Acetic Acid* ; Anti-Bacterial Agents ; Catheters ; Cyst Fluid ; Drainage ; Female ; Follow-Up Studies ; Humans ; Lost to Follow-Up ; Male ; Recurrence ; Sclerotherapy ; Ultrasonography

PURPOSE: To evaluate histopathologic change in the liver after injection of various kinds of sclerosants, andto thus determine whether 50% acetic acid, a new sclerosant, is suitable for percutaneous intrahepatic injection. MATERIALS AND METHODS: Four kinds of clinically available sclerosants were used : 50% acetic acid, 99% ethanol,10% phenol, and hot saline. Each group consisted of ten rats, and 0.1ml of each sclerosant was directly injectedinto the liver. After two days and one week, gross and histopathologic findings of resected liver in the area oftissue necrosis, as well as the degree of extrahepatic peritoneal adhesion, were assessed in each group. RESULTS:In all groups, the main pathologic changes were acute necrosis with inflammation after two days and secondaryregenerative fibrosis after week. In the 50% acetic acid injection group, the degree of necrosis was more severeand the mean diameter of the necrotic area was greater ; this latter was not, however, significantly wider than inthe 99% ethanol injection group, though was significantly wider than in the 10% phenol and hot saline injectiongroup. CONCLUSION: When used for percutaneous injection, 50% acetic acid, caused more tissue necrosis than 99%ethanol, 10% phenol, or hot saline. We therefore conclude that this acid may be useful for percutaneousintrahepatic injection of a hepatic tumor.
Acetic Acid* ; Animals ; Ethanol ; Fibrosis ; Inflammation ; Liver ; Necrosis ; Phenol ; Rats ; Sclerosing Solutions*

BACKGROUND: This study was performed to identify the incidence and prognostic significance of chromosomal abnormalities as well as clinical significance of immuno phenotype in patients with acute myelogenous leukemia (AML). METHODS: The chromosomal abnormalities, immunophenotype and their hematologic/clinical correlations were studied in 68 patients with de novo AML admitted to Pusan National University Hospital between January 1996 and December 2000. 47 of 68 patients had received induction chemotherapy and we analysed the response of treatment according to the karyotype pattern and immunophenotype. RESULTS: The karyotypic patterns were divided into three groups; favorable (t (8;21), t (15;17) and inv (16); n=19, 28%), poor (-5, del (5q), -7, der (1;7), abn (3q) and complex karyotypes; n=11, 16%) and intermediate group (other abnormalities or normal karyotype; n=38, 56%). The incidence of chromosomal abnormalities was 56% (38/68) and overall complete remission (CR) rate of 47 evaluable patients was 64%. The CR rates of favorable, intermediate and poor groups were 88%, 59% and 44%, respectively (p=0.021). The median survival time of all patients was 7 months, those of poor and intermediate groups being 2 months and 6 months. The median survival time of favorable group was not reached (p=0.008). The overall 5 year survival rate was 38% and those of favorable, intermediate and poor groups were 68%, 31% and 9%, respectively (p=0.009). Expression of CD7, CD14, CD33, CD34 and terminal deoxynucleotidyl transferase had no impact on CR rate and overall survival. In multivariate analysis, both age and chromosomal abnormalities influence significantly on prognosis. CONCLUSION: Cytogenetic study is important in predicting the outcome of patients with AML. And the treatment must be tailored according to the result of cytogenetics such as this study.
Adult* ; Busan ; Chromosome Aberrations* ; Cytogenetics ; DNA Nucleotidylexotransferase ; Humans ; Immunophenotyping ; Incidence ; Induction Chemotherapy ; Karyotype ; Leukemia ; Leukemia, Myeloid, Acute* ; Multivariate Analysis ; Phenotype ; Prognosis ; Survival Rate

BACKGROUND: It is well known that various cytokines and growth factors secreted mainly from alveolar macrophages do the key role in the pathogenesis of IPF. But recently it has been known that structural cells like fibroblast can also release cytokines. So the phenotypic changes in fibroblasts of IPF may do a role in continuous progression of fibrosis. The aim of this study is to find out whether there is a change in the biologic properties of the lung fibroblasts of IPF. SUBJECTS AND METHOD: The study was done on 13 patients with IPF diagnosed by open or thoracoscopic lung biopsy and 7 control patients who underwent resectional surgery for lung cancer. Lung fibroblast cell lines (FB) were established by explant culture technique from the biopsy or resected specimen RESULT: Basal proliferation of the fibroblast of IPF(IFB) measured by BrdU uptake tended to be highter than control fibroblast(NFB) (0.212+/- 0.107 vs 0.319+/-0.143, p= 0.0922), also there was no signifrcant difference in proliferation after the stimulation with PDGF or 10% serum. On the contrary, the degree of inhibition in proliferation by PGE2 was significantly lower(33.0+/-13.1%) in IFB than control(46.7+/-10.0%, p= 0.0429). The IFB secreted significantly higher amount of MCP-1(1574+/-1283 pg/ml) spontaneously than NFB(243+/-100 pg/ml) and also after the stimulation with TGF-beta (3.23+/-1.31 ng/ml vs 0.552+/-0.236 ng/ml, p= 0.0012). Similarly IL-8 and IL-6 seretion of IFB was significantly higher than NFB at basal state and with TGF-beta stimulation. But after the maximal stimulation with IL-1beta, no significant difference in cytokine secretion was found between IFB and NFB. CONCLUSION: Above data suggest that the fibroblasts of IPF were phenotypically changed and these change may do a role in the pathogenesis of IPF.
Biopsy ; Bromodeoxyuridine ; Cell Line* ; Culture Techniques ; Cytokines ; Dinoprostone ; Fibroblasts* ; Fibrosis ; Humans ; Idiopathic Pulmonary Fibrosis* ; Intercellular Signaling Peptides and Proteins ; Interleukin-6 ; Interleukin-8 ; Lung Neoplasms ; Lung* ; Macrophages, Alveolar ; Transforming Growth Factor beta